Evidence Hub

(087) Use of Suzetrigine for Post-Operative Pain Management Protocol: Experience at a Single Site

P. Ramirez, M. Neustein, S. Goldstein, I. Goldstein

Journal of Sexual Medicine, 2026

9 participants

Abstract

Abstract Introduction To control post-operative pain, patients are prescribed a regimen that alternates over the counter (OTC) pain medications acetaminophen (1000 mg) with ibuprofen (600 mg) every three hours. When more potent pain relief is required, opioids have been traditionally utilized. Opioids act on the central nervous system (CNS) to bind to opioid receptors, blocking central pain signals. Opioid use, however, is associated with toleration, dependency and compulsive, addictive drug-seeking behavior. On January 30, 2025, the Food and Drug Administration approved the oral, non-opioid suzetrigine (Journavx) for the treatment of moderate-to-severe acute pain in adults. Suzetrigine controls pain by blocking the sodium channel NaV1.8 in the peripheral nervous system thus preventing pain signal transmission to the CNS. Since suzetrigine acts only at the peripheral pain source and not on the CNS, it is non-addictive. Objective This study examined our patients’ self-reports of side effects and benefits of suzetrigine for post-operative pain control used concomitantly with OTC pain meds, with or instead of the opioid oxycodone. Methods Post-operatively patients are regularly queried as to which pain medication(s) were used, dose and timing, side effects experienced, and whether these treatments were successful in ameliorating pain. This study focused on reviewing this data collected at least one month post-operatively as of June 1, 2025. Results A total of 9 women responded…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free